Yamaoka 1994.

Methods	Type of trial: parallel Randomised: yes Allocation concealment: unclear Double‐blinding: yes Study quality: low (because of high dropout rates) Duration of treatment: 4 weeks Cointervention: not available
Participants	Setting: psychiatric OP Diagnosis: major depressive disorder (DSM‐III) Age (mean): 44.4 years Men/women: 8/11 Baseline depressive severity (mean): 26.1 (SD 8.8) on HRSD‐24 Baseline anxiety severity: NS
Interventions	Mianserin 30–60 mg + mexazolam 3 mg
Outcomes	HRSD‐24 up to 4 weeks
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Participants randomised, but no details on how random sequence generated.
Allocation concealment (selection bias)	Unclear risk	Details of allocation concealment not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double blind", "placebo controlled." Further details not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details of outcome assessor blinding not reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	Dropout was a large proportion (4/16 of intervention group and 9/16 of control group) and completer analysis was done.
Selective reporting (reporting bias)	Unclear risk	Study protocol not available; thus, unsure if all of prespecified outcomes of interest reported in prespecified way.
Other bias	Unclear risk	Insufficient information to assess other bias.

CGI: Clinical Global Impression; CPRS: Comprehensive Psychopathological Rating Scale; CPRS‐VAS: Comprehensive Psychopathological Rating Scale – Visual Analogue Scale; DSM‐III: Diagnostic and Statistical Manual 3rd Edition; DSM‐III‐R: Diagnostic and Statistical Manual 3rd Revised Edition; DSM‐IV: Diagnostic and Statistical Manual 4th Edition; HRSD: Hamilton Rating Scale for Depression; IP: inpatient; OP: outpatient; SD: standard deviation; VAS: Visual Analogue Scale.